NasdaqGS:UTHRBiotechs
Will Positive TETON-1 IPF Data and Space R&D Shift United Therapeutics' (UTHR) Innovation Narrative?
United Therapeutics recently reported that its TETON-1 phase 3 study of nebulized Tyvaso in idiopathic pulmonary fibrosis met its primary endpoint, preserving lung function and reducing clinical worsening events, and it entered a collaboration with Varda Space Industries to explore microgravity-based pharmaceutical processing for rare pulmonary diseases.
Beyond reinforcing its pulmonary focus, this combination of positive late-stage IPF data and space-based manufacturing research highlights...